Utilidad de la PET/TC con [18F]F-fluorocolina en la valoración de respuesta a la terapia antiandrogénica en pacientes con cáncer de próstata

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular Pub Date : 2025-03-01 DOI:10.1016/j.remn.2024.500083

K. Quintero , E. Vila , L. Ferrer-Mileo , D. Vas , Maria J. Ribal , M. Garcia-Herreros , N. Navarro , M. Tormo-Ratera , C. Aversa , A. Vilaseca , A. Farré-Melero , D. Fuster , P. Paredes , grupo de Medicina Nuclear Clínic Barcelona (MNCB)

{"title":"Utilidad de la PET/TC con [18F]F-fluorocolina en la valoración de respuesta a la terapia antiandrogénica en pacientes con cáncer de próstata","authors":"K. Quintero , E. Vila , L. Ferrer-Mileo , D. Vas , Maria J. Ribal , M. Garcia-Herreros , N. Navarro , M. Tormo-Ratera , C. Aversa , A. Vilaseca , A. Farré-Melero , D. Fuster , P. Paredes , grupo de Medicina Nuclear Clínic Barcelona (MNCB)","doi":"10.1016/j.remn.2024.500083","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the correlation between response assessment measured by PET/CT with [<sup>18</sup>F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.</div></div><div><h3>Methodology</h3><div>A retrospective study included patients with CRPC and CSPC treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.</div></div><div><h3>Results</h3><div>Thirty patients were included (median age 74 years, range 68-78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5-23).</div><div>Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and ΔSUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA.</div><div>The correlation between PET and PSA was mild <em>(Kendall's tau_b</em> 0.26), and the classification into Responders/Non-responders had only slight agreement (<em>Cohen's kappa</em> 0.30).</div></div><div><h3>Conclusion</h3><div>Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500083"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Medicina Nuclear E Imagen Molecular","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2253654X24001161","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To evaluate the correlation between response assessment measured by PET/CT with [¹⁸F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.

Methodology

A retrospective study included patients with CRPC and CSPC treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.

Results

Thirty patients were included (median age 74 years, range 68-78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5-23).

Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and ΔSUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA.

The correlation between PET and PSA was mild (Kendall's tau_b 0.26), and the classification into Responders/Non-responders had only slight agreement (Cohen's kappa 0.30).

Conclusion

Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Espanola De Medicina Nuclear E Imagen Molecular RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.10

自引率

16.70%

发文量

审稿时长

24 days

期刊介绍： The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members. The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles.